Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 7.64M P/E - EPS this Y 79.90% Ern Qtrly Grth -
Income -15.34M Forward P/E -1.23 EPS next Y 74.80% 50D Avg Chg 4.00%
Sales 7.43M PEG - EPS past 5Y - 200D Avg Chg -23.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -63.00%
Recommedations 2.00 Quick Ratio 1.08 Shares Outstanding 2.18M 52W Low Chg 70.00%
Insider Own 18.30% ROA -65.22% Shares Float 1.88M Beta 1.18
Inst Own 3.82% ROE -3,332.59% Shares Shorted/Prior 93.17K/68.08K Price 0.72
Gross Margin 19.96% Profit Margin -260.86% Avg. Volume 80,172 Target Price 5.00
Oper. Margin -223.44% Earnings Date Oct 24 Volume 20,810 Change -3.38%
About Avinger, Inc.

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.

Avinger, Inc. News
11/08/24 Q3 2024 Avinger Inc Earnings Call
11/08/24 Avinger Inc (AVGR) Q3 2024 Earnings Call Highlights: Strategic Realignment and Product Launches ...
11/07/24 Avinger (AVGR) Reports Q3 Loss, Tops Revenue Estimates
11/07/24 Avinger: Q3 Earnings Snapshot
11/07/24 Avinger Reports Third Quarter 2024 Results
10/29/24 Avinger to Announce Third Quarter 2024 Results on November 7, 2024
10/24/24 Avinger Releases Updated Data From IMAGE-BTK in Webinar Featuring Key Opinion Leaders in the Field of Vascular Intervention
09/18/24 Avinger Announces Issuance of New U.S. Patent and Receives Notices of Allowance for Five Additional U.S. Patents
08/21/24 Avinger (AVGR) Launches Pantheris LV to Boost PAD Treatment
08/20/24 Avinger Initiates Full Commercial Launch of Pantheris LV Image-Guided Atherectomy Device
08/08/24 Avinger (AVGR) Reports Q2 Loss, Lags Revenue Estimates
08/08/24 Avinger: Q2 Earnings Snapshot
08/08/24 Avinger Reports Second Quarter 2024 Results
08/05/24 Avinger Appoints Thomas P. Davis, MD, FACC as Chief Medical Officer
07/29/24 Avinger to Announce Second Quarter 2024 Results on August 8, 2024
06/17/24 Avinger Announces Closing of up to $24 Million Public Offering
06/14/24 Avinger Announces Pricing of up to $24 Million Public Offering
06/05/24 Avinger Increases Focus on Coronary Development, Reduces Operating Costs of Peripheral Business
05/17/24 Are Medical Stocks Lagging Avinger (AVGR) This Year?
05/16/24 Avinger Announces Conversion of $11 Million of CRG Debt into Preferred Equity